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1. Introduction 
The two main forms of the human erythrocyte 
carbonic anhydrase (EC 4.2.1 .l), generally denoted 
B and C, are both metalloenzymes requiring zinc for 
activity and have a molecular weight around 30,000 
[ 1,2] . They catalyze the reversible hydration of car- 
bon dioxide and carbonyl groups of some aldehydes 
and ketones [3] as well as the hydrolysis of certain 
esters. The enzymes are powerfully inhibited by aro- 
matic and heterocyclic sulfonamides and, more weak- 
ly, by monovalent anions. Enzyme B differs from the 
C form in catalytic properties implying structural dis- 
similarities in the active sites. In enzyme B two his- 
tidines of the active site region have been identified by 
chemical modification; one is modifiable with bromo- 
or iodoacetate, and 1 -fluoro-2,4-dinitrobenzene [4-71 
the other with N-chloroacetylchlorothiazide* [8], a 
sulfonamide carrying a reactive group. Human carbon- 
ic anhydrase C is the only form of the enzyme chaiac- 
terized by high-resolution X-ray diffraction [9] but 
has been less extensively studied by chemical moditi- 
cation. A histidine side chain in the active-site region 
has been labelled with bromoacetazolamide [lo] . 
The present paper describes the action of bromo- 
pyruvate on human carbonic anhydrases B and C. Both 
enzymes can be chemically modified apparently in a 
specific reaction taking place with a histidine residue 
at or near the active site. The covalently modified 
*Abbreviations: 
Salamide: S-chloro-2,4disulfamoyl-anilin, 
Ethoxzolamide: 6ethoxy-2-sulfamoyl-1, 3-benzothiazole, 
N-Chloroacetylchlorothiazide: 6-chloro-7-N-chloroacetyl- 
sulfamoyl- 1,2,4_benzothiadiazine 1 ,l dioxide. 
North-Holland Publishing Company - Amsterdam 
enzymes seem to possess residual enzymic activity, 
and may be useful for studies of enzymic mechanism 
as demonstrated for the C enzyme derivative in a re- 
cent kinetic characterization [ 111. 
2. Materials and methods 
Human carbonic anhydrases B and C were prepared 
from erythrocytes [ 121 avoiding lyophilization for 
enzyme (cf. [13]). 
Enzyme activity was determined from the rate of 
hydrolysis of p-nitrophenyl acetate at 25”; for enzyme 
B in Tris-sulfate, pH 7.6, I = 0.075; for enzyme C in 
0.05 M phosphate buffer, pH 6.8.25 1.t1 of 40 mM 
ester in acetone was added to the assay solution 
(2.50 ml) to start the reaction. The change in absor- 
bance was followed at 400 or 348 nm [ 141. The en- 
zyme concentration was generally l-4 PM. Under 
these conditions the concentration of ester substrate 
is far below the Km-value [ 141 and enzyme inhibi- 
tion was treated as non-competitive with respect to 
substrate. Amino acids were analyzed after hydroly- 
sis of the protein or peptide in 6 M HCl for 20 hr at 
110” [ 151.3’~Carboxyketoethylhistidine was deter- 
mined after conversion to 3’-carboxymethylhistidine 
[ 161. Modified histidine was located in the amino acid 
sequences of the enzyme using similar methods as de- 
scribed elsewhere [ 171. 
Bromopyruvic acid from K and K Laboratories 
Inc., Hollywood, Calif., USA was used without fur- 
ther purification. 
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Table 1 
Reversible inhibition of human carbonic anhydrases B and C with bromopyruvic acid and related compounds. 
Enzyme B (pH 7.6) Enzyme C (pH 6.8) 
Concentration Esterase KI Concentration Esterase KI 
Inhibitor of inhibitor activity of inhibitor activity 
(mM) (%) (mM) (mW (%) (mM) 
Bromopyruvic acid 0 100 - 0 100 _ 
0.66 82.4 3.1 8.9 73.0 24 
1.3 70.0 3.1 17.8 58.0 24 
2.6 51.8 3.5 26.1 41.2 24 
6.6 28.3 2.6 35.6 39.2 23 
Mean value 3.1 Mean value 24 
Pyruvic acid 5.1 44 
o-Bromopropionic acid 3.6 38 
Propionic acid 11 48 
Dissociation constants (KZ) for enzyme-inhibitor complexes were estimated from enzyme activity measurements on the rate of 
hydrolysis of p-nltrophenylacetate as described in the Materials and methods section. 
3. Results 
The data in table 1 show that bromopyruvate can 
act as a reversible inhibitor of carbonic anhydrases B 
and C. For both enzymes the reversible complex with 
bromopyruvate seems to be completely inactive as 
judged from the invariant value of the dissociation 
constant (K,) for the complex obtained at different 
concentrations of bromopyruvate (cf. [4] ). The com- 
parisons of bromopyruvate with the other com- 
pounds in table 1 show that the presence of a bro- 
mine atom in the molecule increases the binding 
strength and a similar effect is exhibited by the car- 
bony1 group. 
Prolonged incubation with bromopyruvate leads 
to a decrease of enzymic activity which cannot be 
restored by dilution or dialysis. This irreversible in- 
activation of enzymes B and C is illustrated in figs. 1 
and 2 with the experimental conditions specified in 
the captions to figures. Enzyme B reacted for 1 hr 
has a residual activity of about 4% and contains one 
equivalent of 3’derivative of histidine. The histidine 
modified was found to be identical to the residue modi- 
fiable with bromo- and iodoacetate, and dinitrofluoro- 
benzene, which has tentatively been assigned to posi- 
tion 204 in the enzyme sequence (see [l] ). 
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Fig. 1. Inactivation of human carbonic anhydrase B with 
bromopyruvate. Reaction conditions: 25” ; Tris-sulfate buff- 
er, pH 7.6, Z = 0.075; 0.15 mM carbonic anhydrase; 3.0 mM 
bromopyruvate. From the KZ for the reversible inhibition with 
bromopyruvate (see table 1) 50% of the enzyme should be 
present as reversible complex with inhibitor at the start of 
the reaction. Aliquots of the reaction mixture were with- 
drawn at various times and assayed for enzyme activity as 
described in the Materials and methods section. Half-reac- 
tion time for the loss of activity is 7 min. 
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Fig. 2. Inactivation of human carbonic anhydrase C with 
bromopyruvate. Reaction conditions: 25”; 0.05 M phos- 
phate buffer, pH 6.8; 0.12 mM carbonic anhydrase; 25 mM 
bromopyruvate. From the Kr for the reversible inhibition 
with bromopyruvate (see table 1) about 50% of the enzyme 
should be present as reversible complex with inhibitor at the 
start of the reaction. Aliquots of the reaction mixture were 
withdrawn at various times and used for determination of 
enzyme activity and amino acid composition of reacted 
protein as described in the Materials and methods section. 
For enzyme C (fig. 2) the decrease in enzymic 
activity is slow under the conditions used and levels 
off at about 30% of residual activity. It correlates 
with the formation of one equivalent of modified 
histidine (see fig. 2), suggesting that a specific resi- 
due becomes modified. The following peptide pre- 
paration was isolated from a tryptic digest of modi- 
fied enzyme; Lys Asx~-, Ser Glxs Glyp Ala His 
(modified) Val Be I_eu F’hez . It can be fitted into 
the sequence of protein covering the stretch from 
residue 58 to 76 (see [ 1 ] ). This portion of the 
sequence has not yet been worked out in detail but 
comparisons with other forms of carbonic anhydrase 
[ 181 suggest hat the histidine residue would occupy 
position 64 in the enzyme sequence *. 
The rate of formation of inactivated enzyme C was 
studied at various concentrations of bromopyruvate 
(see table 2). Apparent first-order rate constants (k) 
were estimated for the loss of activity and found to 
be proportional to the fraction of enzyme present as 
reversible complex with reagent (R) in consistency 
with the following scheme: Inacti- 
KI k’ vated 
Et1 \ \ EI ____+ enzyme 
where K, is the dissociation constant for the reversible 
binding of bromopyruvate and k’ the first-order rate 
constant for the conversion of the reversible complex 
into chemically modified enzyme. 
Fig. 3 shows the influence of various enzyme in. 
hibitors on the inactivation of carbonic anhydrase C 
with bromopyruvate. The K, values for salamide and 
KAu(CN), determined here were 1 and 1000 PM, re- 
spectively. For ethoxzolamide, the K1value was found 
to be too low to be possible to estimate with the assay 
used here (K, 4 1 PM) (cf. [2] ). Fig. 3 shows that the 
sulfonamide inhibitors salamide and ethoxzolamide 
partially protect the enzyme while the anionic com- 
plex Au(CN),accelerates the inactivation. 
4. Discussion 
Human carbonic anhydrase B can be specifically 
modified with bromo- and iodoacetate [4 - 61, iodo- 
acetamide [4,6] and, as shown recently in our labor- 
atory, DL-o-bromocaproate [ 193 . These reagents 
bind as reversible inhibitors to the active site and a 
particular histidine residue, supposedly near the posi- 
tion for reversible binding, becomes modified. Bromo- 
pyruvate shows in its action on human enzyme B cer- 
* The numbering of residues in human enzyme C used here 
differs from that of Liljas [9] who uses number 63 for 
this histidine. 
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Table 2 
Inactivation of human carbonic anhydrase C at different con- 
centrations of bromopyruvate. 
Concentration of R 
reagent (mM) 
k(hr-1 x 103) &(hr-lx 103) 
8 0.25 13.7 55 
17 0.41 24.2 61 
35 0.58 28.7 50 
53 0.68 39.6 58 
71 0.74 43.0 58 
--..______. 
Mean value 56 
R is the fraction of enzyme with bromopyruvate reversibly 
bound at the start of the experiment as estimated from the 
iir value in table 1. First- order rate constants (kf for the 
formation of inactivated enzyme were estimated at various 
concentrations of reagent. k’ has been calculated as k/R 
and should correspond to the rate constant for the conver- 
sion of the enzyme-inhibitor complex to chemically modi- 
fied enzyme as in the scheme shown in the text. The value 
of k’ = 0.056 hrW1 found here corresponds to a helf-reac- 
tion time for this conversion of 12.3 hr. The experiments 
were performed at 25” in 0.05 M phosphate buffer, pH 6.8 
with an enzyme concentration of 0.10 mM. Enzyme activity 
was measured under the same conditions using diluted ali- 
quots (see Materials and methods section). 
tain similarities with these reagents. The same histi- 
dine residue becomes modified and the modified 
enzyme appears to have a certain amount of residual 
activity although the reversible enzyme-inhibitor com- 
plex behaves as completely inactive. These similarities 
would suggest common mechanistic features and the 
discussions of the action of bromoacetate, iodoacetate, 
and iodoacetamide on human enzyme B [4- 61 might 
to a considerable extent also apply to bromopyruvate. 
With bromopyruvate the inactivation reaction is signi- 
ficantly faster than with the other reagents in accor- 
dance with the expectation that the halide atom in 
bromopyruvate should be a better “leaving group”. 
Fig. 3. Effects of various carbonic anhydrase inhibitors on 
the inactivation of human carbonic anhydrase C with bromo- 
pyruvate. Reaction conditions: 25”; 0.05 M phosphate buffer, 
pH 6.8; 0.10 mM carbonic anhydrase; 25 mM bromopyruvate. 
Samples were taken after various times and assayed for enzymic 
activity after dilution (see Materials and methods section). k 
and k, are the first-order rate constants estimated for the loss 
of enzymic activity in the presence and absence of inhibitor, 
respectively. EI/E tot represents the fraction of enzyme occur- 
ring as reversible complex with added inhibitor assuming non- 
competitive binding with respect to bromopyruvate. For 1.5 
mM KAu(CN), ,50 and 150 MM &amide, samples of the reac- 
tion product after 69 hr of reaction time were also analyzed 
for modified histidine. The results obtained fitted well with 
the relation between modified histidine and enzymic activity 
shown in fig, 2. 
Table 2 shows that the rate of inactivation of en- activity of the reacted enzyme shows that the modi- 
zyme C is not proportional to the concentration of fiable histidine does not partake in any fundamental 
reagent but to the fraction of enzyme present as re- fashion in the catalytic reaction. Since the reversible 
versible compIex with bromopyruvate. This finding complex, as judged from the data in table 1, appears 
suggests that the modification takes place in the to be completely inactive the high residual activity 
active-site region which is further supported by the would also suggest hat the covalently attached car- 
data in fig. 3 illustrating that enzyme inhibitors in- boxyketoethyl group does not occupy a position iden- 
fluence the rate of inactivation. The high residual tical to that held by the reagent in the reversible com- 
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plex. It is also notable that the formation of irrever- 
sibly modified enzyme is a slow reaction (cf. the rate 
of inactivation of enzyme B). 
The present knowlegde of the primary stiucture of 
the human carbonic anhydrases indicates that histidine 
67 (modifiable with N-chloroacetylthiazide) and histi- 
dine 204 (modifiable with bromo- and iodoacetate, 
iodoacetamide, dinitrofluorobenzene, and bromo- 
pyruvate) in the B enzyme are replaced by other resi- 
dues in enzyme C [ 1 ,171. Both enzymes appear to 
have a histidine residue at position 64 but only in 
enzyme C has this residue been modified with bromo- 
pyruvate. Assuming the same rate of reaction in both 
enzymes, the modification of histidine 64 in enzyme 
B might have escaped detection. It is also possible 
that the carboxyketoethyl group introduced in the 
active site of enzyme B through the rapid reaction 
with histidine 204 prevents the modification of his- 
tidine 64. The results from chemical modifications 
are thus possible to explain without invoking confor- 
mational differences between enzyme B and C. Com- 
bined with X-ray data for crystalline enzyme C [9,1] 
they even provide evidence for similarities between 
the enzymes in peptide chain stretching in the region 
of the active site. According to the X-ray model, resi- 
dues 64,67, and 204 should namely all be parts of 
the active site region. 
The X-ray results suggest hat histidine 64 in native 
enzyme C is hydrogen-bonded to an ordered arrange- 
ment of water molecules present in the active-site 
cavity [9,1] . This arrangement also involves the metal 
ion at the bottom of the cavity which has been ascri- 
bed a central role for the catalytic reaction. Inhibitor 
molecules have in the X-ray studies been observed to 
bind at or close to the metal ion causing a disruption 
and a partial or complete displacement of the ordered 
water. Anionic inhibitors have been reported to bring 
about a change in the properties of histidine 64 obser- 
ved as an increased tendency of this residue to bind 
methylmercurithioglycolic acid [9] . This change, 
possibly due to a release of the hydrogen bonding or re- 
sulting from a small conformational shift, may cause 
the increase in reactivity towards bromopyruvate 
noted here in the presence of Au(CN), (fig. 3). 
Sulfonamide inhibitors bind to carbonic anhydra- 
se with the sulfonamide group oriented towards the 
metal ion [ 1 ] . Salamide has 2 sulfonamide groups 
and X-ray studies on its complex with enzyme C sug- 
gest that the second one (in me&-position) is hydrogen- 
bonded to histidine 64 [ 1,9] . This may explain the 
protective effect of salamide against inactivation with 
bromopyruvate (see fig. 3). It is also possible that fil- 
ling up the active-site cavity with a bulky inhibitor 
could result in a stereochemical hindrance and this 
might be the mechanism behind the protective effect 
found for ethoxzolamide. The considerably smaller 
sulfonamide inhibitor, acetazolamide, does not show 
significant protection, if any [ 191, consistent with the 
X-ray evidence suggesting that in this enzyme-inhibi- 
tor complex histidine 64 remains accessible [9] . 
Several questions, many of these requiring further 
experiments to be answered, can be raised about the 
reversible binding of bromopyruvate. As a monovalent 
anion bromopyruvate would be expected to show af- 
finity for the ordinary inhibitor site at or close to the 
metal ion. The absence of protective effect found for 
KAu(CN), and acetazolamide would, however, sug: 
gest that a reversible binding of a bromopyruvate 
molecule at the ordinary inhibitor site is not a prereq- 
uisite for it to modify. Instead, it appears that the in- 
hibitor position, defined as for KAu(CN), and acetazol- 
amide, does not overlap the space required for a bromo- 
pyruvate molecule to react with histidine 64. Bromo- 
pyruvate differs by containing a carbonyl group from 
the inhibitors so far studied by X-ray diffraction. The 
active site of carbonic anhydrase is known to interact 
with carbonyl groups, namely in the catalytic reaction. 
At present, the possibility cannot be excluded that 
bromopyruvate in the active site becomes oriented as 
a substrate instead of, or in addition to being reversibly 
bound as an anionic inhibitor. The finding that the 
enzyme can act as a catalyst in a closely related sys- 
tem, the dehydration of 2,2-dihydroxypropionate to 
pyruvate, would seem to support such an idea [3]. 
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